Status:
COMPLETED
NRTI-Sparing Pilot Study
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Abbott
Boehringer Ingelheim
Conditions:
HIV
Mitochondrial Toxicity
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will compare a nucleoside reverse transcriptase inhibitor-sparing (NRTI-sparing) regimen (Kaletra + nevirapine) to two nucleoside reverse transcriptase inhibitor-based regimens (Combivir + ...
Eligibility Criteria
Inclusion
- Be HIV-positive
- Be at least18 years of age
- Have viral load above 5 000 copies/ml
- Be likely to comply with the study protocol
- Agree not to take, for the duration of the study, any drug that is contraindicated with the study drugs
- Agree not to take any medication, including over-the-counter medicine, alcohol, or street drugs without the knowledge and permission of the principal investigator
Exclusion
- Have ever received antiretroviral therapy
- Pregnancy or breastfeeding
- Have abnormal laboratory tests (see investigator)
- Have received an investigational drug within 30 days of study drugs administration
- Be receiving systemic chemotherapy
- Have an acute illness
Key Trial Info
Start Date :
April 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00143689
Start Date
April 1 2002
End Date
February 1 2008
Last Update
September 26 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
McMaster University
Hamilton, Ontario, Canada
2
University of Ottawa Health Services
Ottawa, Ontario, Canada
3
Maple Leaf Clinic
Toronto, Ontario, Canada
4
Clinique Medicale L'Actuel
Montreal, Quebec, Canada